Literature DB >> 15353511

Targeted therapy to prevent progression of calcific aortic stenosis.

Nalini M Rajamannan, Catherine M Otto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15353511      PMCID： PMC3951855          DOI： 10.1161/01.CIR.0000140722.85490.EA

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  17 in total

1.  Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons.

Authors:  W S Aronow; C Ahn; I Kronzon; M E Goldman
Journal:  Am J Cardiol       Date:  2001-09-15       Impact factor: 2.778

2.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.

Authors:  B F Stewart; D Siscovick; B K Lind; J M Gardin; J S Gottdiener; V E Smith; D W Kitzman; C M Otto
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

3.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

4.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

5.  Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Margaret Springett; Thomas C Sebo; Marek Niekrasz; Joseph P McConnell; Ravinder J Singh; Neil J Stone; Robert O Bonow; Thomas C Spelsberg
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

6.  HMG CoA reductase inhibitor (statin) and aortic valve calcium.

Authors:  David M Shavelle; Junichuro Takasu; Matthew J Budoff; SongShou Mao; Xue Qiao Zhao; Kevin D O'Brien
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

7.  Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors.

Authors:  K Pohle; R Mäffert; D Ropers; W Moshage; N Stilianakis; W G Daniel; S Achenbach
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 8.  ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity?

Authors:  H C Routledge; J N Townend
Journal:  J Hum Hypertens       Date:  2001-10       Impact factor: 3.012

9.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

Authors:  K D O'Brien; D D Reichenbach; S M Marcovina; J Kuusisto; C E Alpers; C M Otto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-04       Impact factor: 8.311

Review 10.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis.

Authors:  Eva Lonn
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.967
View more
  13 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

2.  Complement up-regulates Runx-2 to induce pro-fibrogenic change in aortic valve interstitial cells.

Authors:  Xin-Sheng Deng; Xianzhong Meng; David Fullerton; Matthew Stone; James Jaggers
Journal:  Ann Thorac Surg       Date:  2021-02-02       Impact factor: 4.330

3.  Is it time for medical therapy for aortic valve disease?

Authors:  Nalini M Rajamannan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

Review 4.  Role of angiogenetic factors in cardiac valve homeostasis and disease.

Authors:  Daihiko Hakuno; Naritaka Kimura; Masatoyo Yoshioka; Keiichi Fukuda
Journal:  J Cardiovasc Transl Res       Date:  2011-08-25       Impact factor: 4.132

Review 5.  One problem two issues! Left ventricular systolic and diastolic dysfunction in aortic stenosis.

Authors:  Maqsood M Elahi; Anthony Chuang; Michael J Ewing; Charles H Choi; Peter W Grant; Bashir M Matata
Journal:  Ann Transl Med       Date:  2014-01

6.  MMP-12-Induced Pro-osteogenic Responses in Human Aortic Valve Interstitial Cells.

Authors:  Xin-Sheng Deng; Xianzhong Meng; Fei Li; Neil Venardos; David Fullerton; James Jaggers
Journal:  J Surg Res       Date:  2018-10-23       Impact factor: 2.192

Review 7.  Lipid lowering and aortic valve disease.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

8.  Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.

Authors:  Cordelia J Barrick; Reade B Roberts; Mauricio Rojas; Nalini M Rajamannan; Carolyn B Suitt; Kevin D O'Brien; Susan S Smyth; David W Threadgill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733

Review 9.  Molecular mechanisms underlying the onset of degenerative aortic valve disease.

Authors:  Daihiko Hakuno; Naritaka Kimura; Masatoyo Yoshioka; Keiichi Fukuda
Journal:  J Mol Med (Berl)       Date:  2008-09-03       Impact factor: 4.599

10.  Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression.

Authors:  Julie A Benton; Hanna B Kern; Leslie A Leinwand; Peter D Mariner; Kristi S Anseth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-13       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.